Navigation Links
Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases

BALTIMORE, Sept. 30, 2013 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceutical company, today announced that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. for GL-2045, Gliknik's recombinant stradomer™, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in a broad range of preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used.

"GL-2045 is the first of several innovative drug candidates Gliknik is advancing for people with autoimmune diseases and cancer," said Gliknik CEO David S. Block. "We selected Pfizer as our partner to progress GL-2045 from among several interested and capable parties because of its exceptional development, manufacturing and commercial capabilities."

Under the terms of the license agreement, Pfizer will receive an exclusive worldwide license to GL-2045 for all therapeutic indications. Gliknik will receive an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments. Gliknik is also eligible to receive tiered, double-digit royalties on net sales of any products that are commercialized pursuant to this license agreement.

"People with certain autoimmune diseases have limited treatment options, difficult regimens and often a poor prognosis," said Jose Carlos Gutierrez-Ramos, Ph.D., group senior vice president and head of Biotherapeutics R&D at Pfizer. "Pooled IVIG has a long history of use but has a number of limitations. We are pleased to partner with Gliknik on this novel therapeutic approach which may provide an important new option in managing debilitating autoimmune diseases."

About GL-2045

GL-2045 is Gliknik's lead preclinical recombinant stradomer™ for autoimmune diseases. It has demonstrated potent efficacy in numerous preclinical tests and is in IND-enabling manufacturing. GL-2045 acts by presenting highly ordered multimers of normal human IgG Fc to its receptors.

About Gliknik Inc.

Founded in 2007, Gliknik is a biopharmaceutical company creating new therapies for patients with cancer and immune disorders. Gliknik's expertise is in modulation of the immune system to fight disease. Gliknik's lead clinical compound is the immune modulator GL-0817 for cancer, which is poised to enter Phase IIb clinical studies. Learn more at

This press release contains "forward-looking statements" concerning the development and commercialization of GL-2045 and other Gliknik products, the potential benefits and attributes of such products, and the possible receipt by Gliknik of future payments. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Gliknik undertakes no obligation to update any forward-looking statements for any reason.

SOURCE Gliknik Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gliknik Adds Incyte President & CEO Paul A. Friedman to its Board of Directors
2. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
3. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
4. CyberKnife System and the da Vinci Surgical System in Concord Medical Centers Achieve Over RMB 10 Million in Medical Revenue Since Opening in February
5. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
6. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
7. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
8. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
9. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
10. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
11. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
Post Your Comments:
(Date:12/1/2015)... --> --> ... by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic ... Analysis - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 40,281.6 Million in 2015, at ... Browse 37 market data T ...
(Date:12/1/2015)... 2015 Assurex Health, Inc. today announced ... healthcare providers an expanded range of options in ... from depression, anxiety, bipolar disorder, posttraumatic stress disorder ... i .   --> ... addition of two new drug classes, 17 FDA-approved ...
(Date:12/1/2015)... , Dec. 1, 2015  Six months of adjunctive metformin ... type 1 diabetes, according to new research from T1D ... it may have a beneficial effect on measures of obesity, ... issue of the Journal of the American Medical Association ... the effect of metformin on overweight and obese adolescents with ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 02, 2015 , ... Ruth Pearson was struggling. She had been laid off ... assistance and quickly losing hope of recovering her former life, Pearson was desperate for ... attending a women’s retreat when she experienced a particularly impactful worship service. Without help ...
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday ... to NASDAQ to educate the personnel on spinal decompression therapy and offer his ... a nonsurgical procedure. The benefits come from creating negative intradiscal pressure which is ...
(Date:12/1/2015)... ... December 01, 2015 , ... Henderson, a ... to receive Gigabit Internet through a partnership this year with Aeneas Internet and ... is an attractive destination for entrepreneurs who want to build a business. Whether ...
(Date:12/1/2015)... ... , ... Florida Hospital Tampa is the first health care provider in the region ... , vBloc® Therapy is a vagal blocking therapy, delivered via the Maestro® System, for the ... (BMI) of at least 40 to 45 kg, or a BMI of at least 35 ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Califia ... today announced that its iconic bottle has won top honors in Beverage World Magazine’s ... The Company also announced that it has been selected as a 2015 U.S.A. Taste ...
Breaking Medicine News(10 mins):